Expressions and roles of long non-coding RNA UCA1 in tumors

doi:10.3760/cma.j.issn.1673-422X.2015.07.011

Abstract

Abstract: Urothelial carcinoma associated antigen 1 (UCA1) is a highly bladder cancerspecific long noncoding RNA (lncRNA), and it does not have the function of encoding protein. UCA1 differentially expresses in various fetal tissues, but its expression is turned off in most adult tissues. It reactivates during tumorigenesis. Researches indicate that UCA1 may regulate cell proliferation, apoptosis, metastasis and chemoresistance of tumors, such as bladder cancer, breast cancer and hepatocellular cancer.

Key words: Neoplasms, Long non-coding RNA, Urothelial carcinoma associated antigen 1

Zhao Yi, Zhang Xingxing, Xu Min. Expressions and roles of long non-coding RNA UCA1 in tumors[J]. Journal of International Oncology, 2015, 42(7): 519-521.

References

［1］ Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future［J］. Genetics, 2013, 193(3): 651-669. ［2］ Ghosal S, Das S, Chakrabarti J. Long noncoding RNAs: new players in the molecular mechanism for maintenance and differentiation of pluripotent stem cells［J］. Stem Cells Dev, 2013, 22(16): 2240-2253. ［3］ Huarte M, Rinn JL. Large noncoding RNAs: missing links in cancer?［J］. Hum Mol Genet, 2010, 19(R2): R152-161. ［4］ Wang XS, Zhang Z, Wang HC, et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma［J］. Clin Cancer Res, 2006, 12(16): 4851-4858. ［5］ Xie XJ, Li X, Wang F, et al. Cellular localization and tissue expression pattern of UCA1, a noncoding RNA［J］. Nan Fang Yi Ke Da Xue Xue Bao, 2010, 30(1): 57-60. ［6］ Wu W, Zhang S, Li X, et al. Ets2 regulates cell apoptosis via the Akt pathway, through the regulation of urothelial cancer associated 1, a long noncoding RNA, in bladder cancer cells［J］. PLoS One, 2013, 8(9): e73920. ［7］ Xue M, Li X, Wu W, et al. Upregulation of long noncoding RNA urothelial carcinoma associated 1 by CCAAT/enhancer binding protein α contributes to bladder cancer cell growth and reduced apoptosis［J］. Oncol Rep, 2014, 31(5): 1993-2000. ［8］ Wang T, Yuan J, Feng N, et al. HsamiR1 downregulates long noncoding RNA urothelial cancer associated 1 in bladder cancer［J］. Tumour Biol, 2014, 35(10): 10075-10084. ［9］ Wang X, Gong Y, Jin B, et al. Long noncoding RNA urothelial carcinoma associated 1 induces cell replication by inhibiting BRG1 in 5637 cells［J］. Oncol Rep, 2014, 32(3): 1281-1290. ［10］ Yang C, Li X, Wang Y, et al. Long noncoding RNA UCA1 regulated cell cycle distribution via CREB through PI3K dependent pathway in bladder carcinoma cells［J］. Gene, 2012, 496(1): 8-16. ［11］ Huang J, Zhou N, Watabe K, et al. Long noncoding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1)［J］. Cell Death Dis, 2014, 5: e1008. ［12］ Hiemer SE, Szymaniak AD, Varelas X. The transcriptional regulators TAZ and YAP direct transforming growth factor βinduced tumorigenic phenotypes in breast cancer cells［J］. J Biol Chem, 2014, 289(19): 13461-13474. ［13］ Jiang M, Huang O, Xie Z, et al. A novel long noncoding RNAARA: adriamycin resistanceassociated［J］. Biochem Pharmacol, 2014, 87(2): 254-283. ［14］ Li JY, Ma X, Zhang CB. Overexpression of long noncoding RNA UCA1 predicts a poor prognosis in patients with esophageal squamous cell carcinoma［J］. Int J Clin Exp Pathol, 2014, 7(11): 7938-7944. ［15］ Wang F, Ying HQ, He BS, et al. Upregulated lncRNAUCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR216b and activation of FGFR1/ERK signaling pathway［J］. Oncotarget, 2015, In press. ［16］ Han Y, Yang YN, Yuan HH, et al. UCA1, a long noncoding RNA upregulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution［J］. Pathology, 2014, 46(5): 396-401. ［17］ Kaneko K, Ito Y, Ono Y, et al. Gene expression profiling reveals upregulated UCA1 and BMF in gallbladder epithelia of children with pancreaticobiliary maljunction［J］. J Pediatr Gastroenterol Nutr, 2011, 52(6): 744-750. ［18］ Yang X, Gao L, Guo X, et al. A network based method for analysis of lncRNAdisease associations and prediction of lncRNAs implicated in diseases［J］. PLoS One, 2014, 9(1): e87797. ［19］ Tian Y, Zhang X, Hao Y, et al. Potential roles of abnormally expressed long noncoding RNA UCA1 and Malat1 in metastasis of melanoma［J］. Melanoma Res, 2014, 24(4): 335-341. ［20］ Liu SP, Yang JX, Cao DY, et al. Identification of differentially expressed long noncoding RNAs in human ovarian cancer cells with different metastatic potentials［J］. Cancer Biol Med, 2013, 10(3): 138-141. ［21］ Fang Z, Wu L, Wang L, et al. Increased expression of the long noncoding RNA UCA1 in tongue squamous cell carcinomas: a possible correlation with cancer metastasis［J］. Oral Surg Oral Med Oral Pathol Oral Radiol, 2014, 117(1): 89-95.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.